Oligonucleotide Aptamer Probes for Disease Biomarker Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic methods lack efficient and specific tools for identifying and targeting disease-specific biomarkers, particularly in bodily fluids, to enable accurate diagnostics and personalized treatment strategies.
Innovation Solution
Development of oligonucleotide probes, or aptamers, that can specifically bind to disease-related biomarkers through mechanisms other than classic Watson-Crick base pairing, allowing for the enrichment and characterization of biological samples, including tissues and microvesicles, to facilitate diagnostic, prognostic, and theranostic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If oligonucleotide probes are used to detect disease biomarkers, then diagnostic precision is improved, but the complexity of the detection system increases
Solution Approach 1:
The detection system is segmented into modular components: oligonucleotide probes with specific sequences for different biomarkers, support structures for immobilization, and detection systems that can be independently optimized. This allows high precision through specialized probe-design while managing overall system complexity through modularity.
Solution Approach 2:
Oligonucleotide probes serve as intermediary molecules that specifically bind to disease biomarkers through non-Watson-Crick interactions. These probes mediate between the complex biological sample and the detection system, enabling precise biomarker detection while simplifying the overall detection architecture through specific molecular recognition.
2Reliability
If oligonucleotide libraries are enriched for disease-specific biomarkers, then therapeutic efficacy is improved, but the time required for treatment customization increases
Solution Approach 1:
Oligonucleotide libraries are pre-enriched with sequences that have affinity for disease-specific biomarkers before clinical use. This preliminary enrichment action allows rapid deployment of customized therapies without requiring time-consuming in-situ library generation, thus improving therapeutic efficacy while minimizing customization time.
Solution Approach 2:
The oligonucleotide libraries undergo parameter changes through enrichment processes that select for sequences with optimal binding characteristics to disease biomarkers. This pre-optimization of binding parameters enables rapid, effective treatment customization by simply selecting the appropriate pre-enriched library for the patient's specific condition.
3Measurement precision
If specific binding interactions are used to target biomarkers, then diagnostic accuracy is improved, but the difficulty of detecting and measuring targets increases
Solution Approach 1:
The system replaces complex mechanical or physical separation methods with molecular recognition-based detection. Oligonucleotide probes use specific non-Watson-Crick binding interactions to automatically recognize and bind to target biomarkers, eliminating the need for complex mechanical separation or purification steps while maintaining high diagnostic accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate detection and characterization of disease phenotypes, predicting drug response, and enabling targeted therapy by enriching oligonucleotide libraries to recognize disease-specific biomarkers, thereby improving diagnostic precision and therapeutic efficacy.
Implementation Method 1
oligonucleotide probes, or aptamers, that can specifically bind to disease-related biomarkers through mechanisms other than classic Watson-Crick base pairing
Data Source
AI summary
Methods and compositions are provided to identify oligonucleotides that bind targets of interest. The targets include tissues, cells, circulating biomarkers such as microvesicles, including those derived from various diseases. The oligonucleotides can be used in diagnostic and therapeutic applications.